Attention all MA plans! Don't let the new Tukey outlier removal methodology catch you off guard in 2024. The upcoming years will be challenging as CMS moves towards a more stringent Star rating system, which means improved performance from contracts is necessary to maintain existing ratings. This can be a significant financial burden, especially for plans that are still struggling with quality initiatives following the pandemic.
But fear not, because quality can become a source of competitive advantage for programs that successfully adjust to the new rating system. Plans that prioritize quality will have a significant advantage in better serving their members and retaining a Star rating of four or above. This will benefit plans in being financially stable, providing rich additional benefits to members, and competing for enrollees who place a high value on Star ratings.
The upcoming changes mean that MA plans need to act now to avoid potential reductions in Star ratings. With a two-year lag between the performance and rating period, plans must anticipate the rise in difficulty and pick up speed now. The good news is that plans can take specific actions to address at-risk indicators, such as establishing a team dedicated to certain measures or developing midyear efforts aimed at improving performance.
Plans should also think about creating a systematic approach to quality spending or boosting expenditure if they currently have one. The return on investment of such investments will likely grow in the future as cut points become more difficult and less erratic. Successful plans have provided front-office workers with quality-focused training, used engaged text messaging, and utilized predictive analytics to initiate call campaigns targeted at patients’ medication adherence.
Don't let the new rating system catch you off guard. Act now to ensure your plan is successful in the future. Contact Saince today to learn more about how our cutting-edge services and expert team can help you streamline your process and improve your MA plan's Star rating. Our customizable services cater to your specific needs, ensuring that you only pay for what you need. Trust us to help you stay ahead of the competition and succeed in the new rating system.
This measure's weight is 1 (medium importance)
This measure's weight is 3 (medium importance)
This measure's weight is 1 (medium importance)
This measure's weight is 1 (medium important)
This measure's weight is 1 (medium importance)
This measure's weight is 1 (medium importance)
This measure's weight is 3 (very important)
This measure's weight is 1 (medium importance)
This measure's weight is 1 (medium importance)
This measure's weight is 1 (medium importance)
Moderate to high intensity Statin Therapy Cardiovascular Disease males 21-75, females 40-75
This measure's weight is 1 (medium importance)
Moderate to high intensity Statin Therapy Cardiovascular Disease males 21-75, females 40-75.
This measure's weight is 0.5 (medium importance)
Moderate to high intensity Statin Therapy Cardiovascular Disease males 21-75, females 40-75.
This measure's weight is 3 (very important)
Medications: Biguanides, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, GLP-1 receptor agonist, meglitinides and SGLT2 inhibitors.
This measure's weight is 3 (very important)
Medications: ACE inhibitors, ARBs, Direct Renin Inhibitors or combination
This measure's weight is 3 (very important)
Medications: TIER 1 and TIER 2
This measure's weight is 1 (medium importance)
Medications: Statins TIER 1 and TIER 2.
Eligible members are males between ages 21 to 75 and females from 40 to 75 with diagnosis of cardiovascular disease and or Diabetes.
The range should be Moderate to High intensity Statins.
This measure's weight is 1 (medium important)